Japan Lung Cancer Society Information
Japan Lung Cancer Society Information
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
Japan Lung Cancer Society Information
- December 21, 2015
- Read time: 2 minutes
Several colleagues of Japanese nationality have inquired about recent immunotherapy information. They asked if we could provide updates. Please follow our Facebook page.
What Medical Supporter can do is make your medical care more convenient and hassle-free. Frankly, in this information-saturated age, there's little that cannot be accomplished. Below are two recent articles published by the Japan Lung Cancer Society.
Information 1: http://www.haigan.gr.jp/uploads/photos/1079.pdf
This is the Japan Lung Cancer Society's recommendation from December 11, 2015 regarding PD-1 drug subsidies. They recommend modifications to the DPC system. Details are available via the link. Current Opdivo costs vary by body weight, but in Japan average approximately 3 million yen per month. Due to Japan's high-cost medical expense subsidy system, patients typically pay around 100,000 yen, then 45,000 yen from the fourth month onward. However, the current issue is the hospital's maximum reimbursement ceiling. They proposed reducing hospital losses and providing more complete information to patients.
Information 2: http://www.haigan.gr.jp/uploads/photos/1078.pdf
This article is for Japan Lung Cancer Society members and discusses Iressa. When Iressa first came to market, its risk of interstitial pneumonia side effects wasn't yet known, resulting in over 800 patient deaths. The Japan Lung Cancer Society emphasizes that medical professionals should carefully evaluate whether Opdivo is appropriate for each patient and stay informed about subsidy updates.
Quote: "In the past, the 'dream new drug' Iressa emerged. When it first appeared, the dangers of interstitial pneumonia were unknown, and over 800 people died. In considering Nivolumab's approval and use, we must not forget this lesson. We believe this applies not only to medical professionals but also to patients."
#Related to Immunotherapy Efficacy #Related to Immunotherapy #Lung Cancer
-
Immunotherapy
(Solid Tumors) Is Keytruda Effective? (Solid Tumors) Rakuten Medical RM-1995 Photoimmunotherapy Phase I Clinical Trial Launch (Lung Cancer) Is Keytruda Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4